Quick Answer
PLIANT THERAPEUTICS, INC. reported Research And Development Expense of $109.16 million for the year ending 2025.
- PLIANT THERAPEUTICS, INC. showed a decrease of -35.5% in Research And Development Expense from 2024 to 2025.
- This data is from PLIANT THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $13.10 million | Q3 2019: $10.78 million | Q1 2020: $13.92 million | Q2 2020: $17.54 million | Q3 2020: $16.88 million | Q1 2021: $18.53 million | Q2 2021: $19.22 million | Q3 2021: $21.05 million | Q1 2022: $20.88 million | Q2 2022: $26.34 million | Q3 2022: $24.61 million | Q1 2023: $29.27 million | Q2 2023: $33.00 million | Q3 2023: $32.34 million | Q1 2024: $37.15 million | Q2 2024: $45.62 million | Q3 2024: $47.75 million | Q1 2025: $43.44 million | Q2 2025: $32.20 million | Q3 2025: $17.94 million.
- Over the full 7 years of available data (2019 to 2025), PLIANT THERAPEUTICS, INC.'s Research And Development Expense has grown by 130.5%.
- Historical annual values: Fiscal year 2025: $109.16 million | Fiscal year 2024: $169.31 million | Fiscal year 2023: $127.80 million | Fiscal year 2022: $96.94 million | Fiscal year 2021: $77.55 million | Fiscal year 2020: $66.19 million | Fiscal year 2019: $47.35 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: